U.S. nicotine pouch brand 2ONE Labs says 2ONE® gains FDA “approval”

Oct.30.2024
U.S. nicotine pouch brand 2ONE Labs says 2ONE®  gains FDA “approval”
U.S. nicotine pouch brand 2ONE Labs announces its product 2ONE® has received Premarket Tobacco Product Application (PMTA) “approval” from the FDA, marking its progression to the next stage in the FDA review process.

2ONE Labs announced on October 29 that its 2ONE® brand of nicotine pouches has received approval from FDA for its Pre-Market Tobacco Product Application (PMTA), according to Globe Newswire.

 

U.S. nicotine pouch brand 2ONE Labs says 2ONE®  gains FDA “approval”
Translation into English: Nicotine pouch brand "2ONE" from 2ONE Labs | Image source: 2ONE Labs official website

 

After receiving the “approval” notification from the FDA, 2ONE Labs CEO Vincent Schuman stated:

 

“This signifies that the PMTA application for 2ONE® has advanced to the next critical phase of the FDA review process. Our company will continue to provide financial backing to ensure the successful completion of this submission. Our wholesale, retail, and sponsorship partners should view this ‘approval’ as a testament to our ability to navigate the complex PMTA process and our firm commitment to supporting the long-term availability of the 2ONE® brand in the U.S. market.”

 

“The 2ONE® nicotine pouches were developed for adult users (21+) who face challenges transitioning from combustible tobacco or traditional oral tobacco products to alternative options. Over the past five years, the 2ONE® brand has garnered market attention and growth, thanks to strong distribution partnerships like those with CircleK®. FDA’s approval of 2ONE®’s PMTA application is exciting, and we look forward to continuing to support adult consumers seeking alternatives to traditional tobacco products.”

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement
President Donald Trump signed the Continuing Appropriations Act, 2026 (H.R.5371) on November 12, Section 772 of Part B—the Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act (S.2256)—requires the FDA to allocate no less than $200 million in tobacco user fees to enforce regulations against illegal e-cigarettes, vapes, and other ENDS products. At least $2 million of this funding supports a federal multi-agency task force targeting products originating from the China.
Nov.14 by 2FIRSTS.ai
Philippines Probe Agency Seizes 800 Smuggled Vape Products in Manila, Stores Face Multiple Charges
Philippines Probe Agency Seizes 800 Smuggled Vape Products in Manila, Stores Face Multiple Charges
The National Bureau of Investigation (NBI) recently seized around PHP 250,000 (approximately USD 4,250) worth of smuggled and unregistered vape devices and liquids—about 800 items in total—from two stores in Manila. Authorities said the devices could be modified to discreetly consume cannabinoids and other illegal drugs, and that those involved will face charges under the Philippines’ Vaporized Nicotine and Non-Nicotine Products Regulation Act and the Consumer Act.
Dec.02 by 2FIRSTS.ai
British American Tobacco’s Irish unit says VELO pouch sales hit 29m, net revenue climbs to €33.75m
British American Tobacco’s Irish unit says VELO pouch sales hit 29m, net revenue climbs to €33.75m
British American Tobacco’s Irish subsidiary PJ Carroll & Co Ltd reported that sales of its Velo nicotine pouches nearly quintupled in 2024 to 29 million units, driving an 11% year-on-year increase in net revenue to €33.75 million. However, amid a heavy tax burden and declining traditional cigarette volumes, the company’s pre-tax profit fell 8% to €5.69 million.
Dec.01 by 2FIRSTS.ai
Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
Product | 2× “2+10” configuration, rated 36,000 puffs — VOZOL launches NEON PLUG MAX
VOZOL has listed a new product, NEON PLUG MAX, on its official website, featuring dual 2 ml prefilled pods and dual 10 ml refill bottles (24 ml total), a claimed maximum of 36,000 puffs, and two-flavour switching. The device was previously shown at InterTabac 2025 and was listed by the UK MHRA in March 2025; however, as of publication it was not yet available on overseas retail sites.
Oct.22 by 2FIRSTS.ai
Philip Morris Korea: IQOS ILUMA i “SELETTI” Limited Edition Sells Out in One Week; Prime Model Sells Out on Launch Day
Philip Morris Korea: IQOS ILUMA i “SELETTI” Limited Edition Sells Out in One Week; Prime Model Sells Out on Launch Day
Philip Morris Korea and Italian design brand SELETTI’s limited “IQOS ILUMA i × SELETTI” collection sold out within one week of launch, with the “Prime” model selling out on its first day of release.
Nov.11 by 2FIRSTS.ai
IMiracle  Announces 2025 R&D Progress with Over 2,200 Patent Applications Worldwide
IMiracle Announces 2025 R&D Progress with Over 2,200 Patent Applications Worldwide
IMiracle announces significant R&D progress in 2025, with over 2,200 patent applications globally and 900 authorized patents.
Dec.18 by 2FIRSTS.ai